Harvard Bioscience, Inc. (HBIO) P/E Ratio History
Historical price-to-earnings valuation from 2002 to 2015
Loading P/E history...
HBIO Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Harvard Bioscience, Inc. (HBIO) trades at a price-to-earnings ratio of -5.3x, with a stock price of $6.79 and trailing twelve-month earnings per share of $-1.28.
The current P/E is 100% below its 5-year average of 1138.6x. Over the past five years, HBIO's P/E has ranged from a low of 42.0x to a high of 8558.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, HBIO trades at a 124% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, HBIO trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our HBIO DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
HBIO P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $1B | 20.2Lowest | 0.66Best | +8% | |
| $2B | 42.8 | 2.21 | +31%Best | |
| $23B | 32.6 | 6.29 | +0% | |
| $8B | 110.7 | - | -56% | |
| $176B | 26.8 | 12.67 | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
HBIO Historical P/E Data (2002–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q1 | $58.20 | $0.01 | 8558.8x | +790% | |
| FY2014 Q4 | Wed Dec 31 2014 00:00:00 GM | $56.70 | $0.07 | 817.0x | -15% |
| FY2014 Q3 | $40.90 | $0.05 | 877.7x | -9% | |
| FY2013 Q3 | Mon Sep 30 2013 00:00:00 GM | $40.20 | $0.00 | 8204.1x | +753% |
| FY2013 Q2 | Sun Jun 30 2013 00:00:00 GM | $35.90 | $0.03 | 1104.6x | +15% |
| FY2013 Q1 | Sun Mar 31 2013 00:00:00 GM | $43.10 | $0.07 | 630.1x | -35% |
| FY2012 Q4 | Mon Dec 31 2012 00:00:00 GM | $33.50 | $0.09 | 392.3x | -59% |
| FY2012 Q3 | Sun Sep 30 2012 00:00:00 GM | $32.30 | $0.08 | 428.4x | -55% |
| FY2012 Q2 | Sat Jun 30 2012 00:00:00 GM | $28.80 | $0.08 | 356.0x | -63% |
| FY2012 Q1 | Sat Mar 31 2012 00:00:00 GM | $29.90 | $0.10 | 296.3x | -69% |
| FY2011 Q4 | Sat Dec 31 2011 00:00:00 GM | $29.60 | $0.14 | 210.1x | -78% |
| FY2011 Q3 | Fri Sep 30 2011 00:00:00 GM | $32.20 | $0.19 | 168.7x | -82% |
Average P/E for displayed period: 962.1x
See HBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHBIO — Frequently Asked Questions
Quick answers to the most common questions about buying HBIO stock.
Is HBIO stock overvalued or undervalued?
HBIO trades at -5.3x P/E, below its 5-year average of 1138.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does HBIO's valuation compare to peers?
Harvard Bioscience, Inc. P/E of -5.3x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is HBIO's PEG ratio?
HBIO PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2002-2015.